EICHOR
● Recruiting
Single cEll pRofiling PErsistaNce To ImmuNothErapy
Condition: Colorectal Cancer · Endometrial Cancer · Sponsor: Vall d'Hebron Institute of Oncology
About this study
The SERPENTINE trial (ESR 21-21165) is a phase II clinical study aiming to evaluate the efficacy of durvalumab and tremelimumab, alone or in combination, in patients with colorectal or endometrial cancer. The trial targets patients with microsatellite instability-high (MSI-H) tumors and those with microsatellite stable (MSS) tumors. Colorectal and endometrial cancers present significant challenges due to their heterogeneity and variable responses to treatment. Immunotherapy, particularly checkpoint inhibitors like durvalumab and tremelimumab, has shown promise in some patients, but predicting response remains elusive. The SERPENTINE trial aims to address this gap by investigating the effectiveness of these immunotherapies in a carefully selected patient population.
This description comes directly from the study's public registry record.
Talk to the study team
Elena Elez, MD PhD · +34 932744350 · meelez@vhio.net
Susana Muñoz · smunoz@vhio.net
Always discuss trial participation with your own doctor first.
Locations (1)
| Vall d'Hebron Institute of Oncology | Barcelona, Spain | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06680739